Impaired hematopoietic differentiation of RUNX1-mutated induced pluripotent stem cells derived from FPD/AML patients

Leukemia

Volumn 28, Issue 12, 2014, Pages 2344-2354

  Sakurai, M ^a   Kunimoto, H ^a   Watanabe, N ^a   Fukuchi, Y ^a   Yuasa, S ^a   Yamazaki, S ^b   Nishimura, T ^c   Sadahira, K ^a   Fukuda, K ^a   Okano, H ^a   Nakauchi, H ^b,c   Morita, Y ^d   Matsumura, I ^d   Kudo, K ^e   Ito, E ^e   Ebihara, Y ^f   Tsuji, K ^c,f   Harada, Y ^g,h   Harada, H ^g,h   Okamoto, S ^a   Nakajima, H ^a   more..

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

^f THE UNIVERSITY OF TOKYO   (Japan)

^g HIROSHIMA UNIVERSITY   (Japan)

^h JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; GLYCOPROTEIN IB ALPHA; KRUPPEL LIKE FACTOR 4; LEUKOSIALIN; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR SOX2;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL MATURATION; COCULTURE; COLONY FORMING CELL; DNA BINDING; EMBRYONIC STEM CELL; FAMILIAL DISEASE; FAMILIAL PLATELET DISORDER; FLOW CYTOMETRY; GENE OVEREXPRESSION; HEMATOPOIESIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; MEGAKARYOCYTE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PEDIGREE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENDAI VIRUS INFECTION; STROMA CELL; THROMBOCYTE DISORDER; WESTERN BLOTTING; WILD TYPE; ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; FEMALE; GENE EXPRESSION; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOPHENOTYPING; MALE; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ANIMALS; BLOOD PLATELET DISORDERS; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; INDUCED PLURIPOTENT STEM CELLS; LEUKEMIA, MYELOID, ACUTE; MALE; MEGAKARYOCYTES; MICE; MUTATION; PEDIGREE; PHENOTYPE;

EID: 84925285887     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.136     Document Type: Article

References (45)

1. Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, Yamagata T et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004; 10: 299-304.
2. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 2004; 23: 4284-4296.
3. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, Inaba T. High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 2004; 103: 2316-2324.
4. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004; 104: 1474-1481.
5. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T. Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 2003; 101: 673-680.
6. Zharlyganova D, Harada H, Harada Y, Shinkarev S, Zhumadilov Z, Zhunusova A et al. High frequency of AML1/RUNX1 point mutations in radiation-associated myelodysplastic syndrome around Semipalatinsk nuclear test site. J Radiat Res 2008; 49: 549-555.
7. Kuo MC, Liang DC, Huang CF, Shih YS, Wu JH, Lin TL et al. RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation. Leukemia 2009; 23: 1426-1431.
8. Ernst T, Chase A, Zoi K, Waghorn K, Hidalgo-Curtis C, Score J et al. Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms. Haematologica 2010; 95: 1473-1480.
9. Matheny CJ, Speck ME, Cushing PR, Zhou Y, Corpora T, Regan M et al. Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J 2007; 26: 1163-1175.
10. Harada Y, Harada H. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations. J Cell Physiol 2009; 220: 16-20.
11. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002; 99: 1364-1372.
12. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, Maki K et al. Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 2000; 96: 3154-3160.
13. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-175.
14. Higuchi M, O'Brien D, Kumaravelu P, Lenny N, Yeoh EJ, Downing JR. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 2002; 1: 63-74.
15. Motoda L, Osato M, Yamashita N, Jacob B, Chen LQ, Yanagida M et al. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells 2007; 25: 2976-2986.
16. Jacob B, Osato M, Yamashita N, Wang CQ, Taniuchi I, Littman DR et al. Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis. Blood 2010; 115: 1610-1620.
17. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
18. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
19. Chou ST, Byrska-Bishop M, Tober JM, Yao Y, Vandorn D, Opalinska JB et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci USA 2012; 109: 17573-17578.
20. Ye Z, Zhan H, Mali P, Dowey S, Williams DM, Jang YY et al. Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood 2009; 114: 5473-5480.
21. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877-886.
22. Hiramoto T, Ebihara Y, Mizoguchi Y, Nakamura K, Yamaguchi K, Ueno K et al. Wnt3a stimulates maturation of impaired neutrophils developed from severe congenital neutropenia patient-derived pluripotent stem cells. Proc Natl Acad Sci USA 2013; 110: 3023-3028.
23. Maclean GA, Menne TF, Guo G, Sanchez DJ, Park IH, Daley GQ et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci USA 2012; 109: 17567-17572.
24. Chang CJ, Bouhassira EE. Zinc-finger nuclease-mediated correction of alpha-thalassemia in iPS cells. Blood 2012; 120: 3906-3914.
25. Carette JE, Pruszak J, Varadarajan M, Blomen VA, Gokhale S, Camargo FD et al. Generation of iPSCs from cultured human malignant cells. Blood 2010; 115: 4039-4042.
26. Kumano K, Arai S, Hosoi M, Taoka K, Takayama N, Otsu M et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012; 119: 6234-6242.
27. Gandre-Babbe S, Paluru P, Aribeana C, Chou ST, Bresolin S, Lu L et al. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood 2013; 121: 4925-4929.
28. Seki T, Yuasa S, Fukuda K. Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat Protoc 2012; 7: 718-728.
29. Fukuchi Y, Shibata F, Ito M, Goto-Koshino Y, Sotomaru Y, Ito M et al. Comprehensive analysis of myeloid lineage conversion using mice expressing an inducible form of C/EBP alpha. EMBO J 2006; 25: 3398-3410.
30. Ma F, Wang D, Hanada S, Ebihara Y, Kawasaki H, Zaike Y et al. Novel method for efficient production of multipotential hematopoietic progenitors from human embryonic stem cells. Int J Hematol 2007; 85: 371-379.
31. Ma F, Ebihara Y, Umeda K, Sakai H, Hanada S, Zhang H et al. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci USA 2008; 105: 13087-13092.
32. Takayama N, Nishikii H, Usui J, Tsukui H, Sawaguchi A, Hiroyama T et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 2008; 111: 5298-5306.
33. Nakajima H, Ito M, Smookler DS, Shibata F, Fukuchi Y, Morikawa Y et al. TIMP-3 recruits quiescent hematopoietic stem cells into active cell cycle and expands multipotent progenitor pool. Blood 2010; 116: 4474-4482.
34. Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010; 7: 11-14.
35. Xu MJ, Tsuji K, Ueda T, Mukouyama YS, Hara T, Yang FC et al. Stimulation of mouse and human primitive hematopoiesis by murine embryonic aorta-gonadmesonephros-derived stromal cell lines. Blood 1998; 92: 2032-2040.
36. Vodyanik MA, Thomson JA, Slukvin II. Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood 2006; 108: 2095-2105.
37. Choi KD, Yu J, Smuga-Otto K, Salvagiotto G, Rehrauer W, Vodyanik M et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells 2009; 27: 559-567.
38. Dowdy CR, Xie R, Frederick D, Hussain S, Zaidi SK, Vradii D et al. Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation. Hum Mol Genet 2010; 19: 1048-1057.
39. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1 the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321-330.
40. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci USA 1996; 93: 3444-3449.
41. North T, Gu TL, Stacy T, Wang Q, Howard L, Binder M et al. Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development 1999; 126: 2563-2575.
42. North TE, de Bruijn MF, Stacy T, Talebian L, Lind E, Robin C et al. Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity 2002; 16: 661-672.
43. Lancrin C, Sroczynska P, Stephenson C, Allen T, Kouskoff V, Lacaud G. The haemangioblast generates haematopoietic cells through a haemogenic endothelium stage. Nature 2009; 457: 892-895.
44. Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E, Speck NA. Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 2009; 457: 887-891.
45. Ran D, Shia WJ, Lo MC, Fan JB, Knorr DA, Ferrell PI et al. RUNX1a enhances hematopoietic lineage commitment from human embryonic stem cells and inducible pluripotent stem cells. Blood 2013; 121: 2882-2890.